Sucralfate is an aluminum hydroxide complex of sucrose octasulfate. It acts as a protective agent and forms an ulcer-healing complex with proteins at the ulcer site. Sucralfate demonstrates cytoprotective properties by forming a physical barrier at the gastric mucosa that shields the underlying tissue from acid assault and pepsin activity. It also stimulates prostaglandin formation to increase mucosal blood flow and aids in ulcer healing. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), and other gastrointestinal ulcers or erosions.

The U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market key trends:
One of the key trends fueling the growth of the U.S. sucralfate market is the rising prevalence of peptic ulcers in the country. Peptic ulcers are open sores or ulcers that develop in the lining of the esophagus, stomach, or the first part of the small intestine. A few common risk factors that contribute to the rising incidence of peptic ulcers include excessive consumption of non-steroidal anti-inflammatory drugs (NSAIDs), smoking, excessive alcohol intake, bacterial infection with H. pylori, and stress. According to the American Gastroenterological Association, about 15 million Americans suffer from peptic ulcers each year. The higher occurrence of ulcers would correspondingly boost the demand for sucralfate in the U.S. ulcer healing market.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the U.S. sucralfate market is low as it requires high investment in R&D and manufacturing facilities. Bargaining power of buyers: The bargaining power of buyers is moderate as sucralfate is available on prescription and there are few substitutes available. Bargaining power of suppliers: The bargaining power of suppliers is moderate as the raw materials required are commodity products and suppliers have the threat of forward integration. Threat of new substitutes: New substitutes pose low threat as sucralfate offers unique mechanism of action for treatment of ulcers. Competitive rivalry: Intense as major players compete on brand recognition, quality and pricing.

SWOT Analysis
Strength: Sucralfate offers gastric protection without systemic absorption and has fewer side effects. Wide range of drugs available in tablet, suspension and syrup forms.

Weakness: Requires frequent dosing. Taste of sucralfate formulations is generally unpalatable.

Opportunity: Increasing prevalence of peptic ulcers and GERD presents growth opportunities. New innovative formulations can improve patient compliance.

Threats: Generic competition poses pricing pressure. Safety concerns over long-term usage can impact demand.

Key Takeaways
The global U.S. Sucralfate Market Size is expected to witness high growth, exhibiting CAGR of 4.2% over the forecast period, due to increasing prevalence of peptic ulcers in the country. Regionally, the western U.S. holds the largest share currently due to higher awareness and faster adoption of new drugs. The northeast U.S. is expected to be the fastest growing market due to rising healthcare expenditures.

Key players operating in the U.S. sucralfate market are Sanofi, Teva Pharmaceutical Industries, Taro Pharmaceuticals, Mylan N.V., and Perrigo Company PLC. Sanofi dominates the market with over 30% share due to its wide portfolio of branded sucralfate products. Teva Pharmaceutical Industries holds the second largest market share with generic sucralfate drugs.

Explorer more information on this topic, Please visit @ https://www.rapidwebwire.com/driving-the-growth-of-u-s-sucralfate-market-size